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Pharmacoeconomics is a rapidly expand-
ing field with interests from the whole
gamut of health-related personnel, span-
ning from hospital administrators to
policy makers (Drummond et al., 2003). It
incorporates various analytical techniques
that deal with costs and outcomes of
pharmaceutical interventions employed in
prevention, diagnosis, treatment andman-
agement of diseases. Pharmacoeconomic
evaluation is concerned with the com-
parison of two or more drug therapies
with respect to their costs and conse-
quences. Considered a branch of health
economics, pharmacoeconomics limits
itself to the pharmaceutical facet of health-
care system. Cost-minimization analysis,
cost-effectiveness analysis, cost-utility
analysis, and cost-consequence analysis are
chief types of pharmacoeconomic studies
(Drummond, 2006). These studies are car-
ried out from the perspectives of patient,
payer, or society, these perspectives dif-
fering in the type of costs included in the
studies (Drummond, 2006). That pharma-
coeconomic studies are highly regarded by
health-care experts and policy makers for
basing health policy decisions, emphasize
their significance (Greenberg et al., 1999).
These studies are of immense significance
to pharmaceutical industries as well, the
research and development of newer drugs
and critical decisions regarding them
being influenced by results of pharma-
coeconomic studies in many instances
(DiMasi et al., 2001).
Pharmacoeconomic studies are a reg-
ular in most of the countries, both
developed and developing. They are car-
ried out in academic institutions—with
vested academic interest—as well as by
certain organizations (Drummond et al.,
2003). In countries like Australia and
Canada, the results of these studies for
new pharmaceuticals need to be sub-
mitted to the Government—these coun-
tries have mandatory pharmacoeconomic
guidelines—for reimbursement purpose
(Hjelmgren et al., 2001). In US, manda-
tory guidelines on Government’ part
are not available; however, insurance
companies have their separate set of
guidelines for reimbursement on their
part—health insurance coverage in US
comes from many private insurance com-
panies (third party payers) (Hjelmgren
et al., 2001). Asian countries such as Japan,
Korea, China, Singapore, Hongkong, and
Taiwan are also making a rapid progress
in pharmacoeconomic aspect of health
system—they are still behind the Western
countries, though (Doherty et al., 2004).
India is also realizing the gravity of phar-
macoeconomic studies in the realm of
health sector, and requisite steps are being
taken for consolidating pharmacoeco-
nomic studies in the country (Thakkar
and Billa, 2013). International Society
for Pharmacoeconomics and Outcomes
Research (ISPOR), with membership from
115 countries, has been contributing to
the spread of significance of pharmacoeco-
nomic studies within the health-care sys-
tem. Pharmacoeconomic studies are thus
starting to gain a foothold in the global
health sector, with many countries start-
ing to incorporate these studies in their
health-care system.
Nepal is a small, mountainous country
situated in the southeastern region of Asia.
It is sandwiched between India and China.
Nepal is a least developed country which
is ranked 157th in Human Development
Index (UNDP, 2011), this lower rank-
ing reflecting the socio-economic status
of the country. The protracted political
imbroglio and the time-and-again insur-
gency by political parties and combatant
groups—Maoists’ insurgency being the
latest and arguably the most threatening—
have hampered the progress of the coun-
try. Weak governance, incapacitated public
sector, slow recovery from civil conflicts,
inadequate infrastructures—chiefly, trans-
portation and electricity—and mediocre
industrial performance have been the
seminal factors for poor performance of
Nepal in socio-economic index (Asian
Development Bank, 2009). There is a con-
siderable disparity in socioeconomic sta-
tus among people from different topo-
graphical regions (Asian Development
Bank, 2009). Marred by political turmoil
and sluggish socio-economic progress,
Nepal has not done much to make its
mark on socio-economic and political
front in the international arena. Health
sector has also faced the repercussions
of these socio-economic and political
upheavals.
Health sector of Nepal is toddling its
way and has had its share of achievements
and disappointments in recent years.
Millennium Development Goals (MDGs)
for maternal mortality rate and child mor-
tality rate have already been achieved
by Nepal (Government of Nepal, 2013).
However, there are other dimensions of
health sector that are not fully addressed,
not least is the inequitable distribu-
tion of health services among different
geographical and socio-economic groups.
There is a considerable disparity in the
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health services available for people of rural
and urban areas, for people from privi-
leged families, and those from marginal-
ized ones, and for people from different
age and gender groups (Government of
Nepal, 2013). Moreover, the quality of
health services is not up to the interna-
tional standards. Also, a lion’s share of
public sector health expenditure comes
from foreign donors (Ministry of Health
and Population, 2010), thereby accentu-
ating the fragile state of the health sec-
tor. Pharmaceutical division, among var-
ious sections of the health sector, has
not done anything monumental, but is
headed in the right direction (Budhathoki,
2012). Increasing number of pharma-
ceutical industries, production of high
quality medicines, and their lower price
compared to imported medicines are a
few positives of Nepal’s pharmaceuti-
cal sector; however, it is also strewn
with shortcomings such as mediocre
research and development, absence of raw
materials (active pharmaceutical ingredi-
ents) manufacturers, and fierce competi-
tion with foreign-manufactured products
(Budhathoki, 2012). Against this backdrop
of pharmaceutical sector, pharmacoeco-
nomic studies are virtually non-existent in
Nepal.
Government’s expenditure in health is
a meager 5.3 percent of GDP and per
capita health expenditure is USD18.09,
as per 2006 data (Ministry of Health
and Population, 2010). If this is jux-
taposed against the data from devel-
oped countries like the United States,
Japan—per capita health care expenditure
being USD8,608 for US and USD3,958
for Japan (Davidson, 2013)—the state
of public spending in health of Nepal
becomes all the more apparent. In addi-
tion, more than 55 percent of total health
expenditure comes from out-of-pocket
health expenditure (Ministry of Health
and Population, 2010). With such lim-
ited spending in health sector on public
sector’s part and with people dishing out
money for health services as per their eco-
nomic status, pharmacoeconomic studies
have become highly desirable to ascer-
tain accessibility of one and all to health
services.
National Drug Policy-1995 of Nepal has
no mention of pharmacoeconomic stud-
ies (Department of Drug Administration,
1995). These studies have been viewed as
a prerogative of health sector of devel-
oped countries, with Nepal still grap-
pling to provide basic health facilities
and essential medicines to the pub-
lic. On the contrary, the significance of
these studies becomes more glaring in
such situations, where wise spending in
health services, including medicines, is
paramount. The likes of cost-effectiveness
and cost-minimization analysis help deter-
mine cost effective medicines for different
diseases. The findings from these stud-
ies could be internalized, which could
lead to availability of better medicines
with considerable saving of public sec-
tor’s fund. Moreover, the country is gear-
ing up for materializing community-based
health insurance program, with the aim
of establishing universal health coverage;
in fact, pilot programs have already been
carried out in a few districts (GIZ, 2012).
Formulary making and reimbursement
decisions are next steps to follow, and
pharmacoeconomic evaluation is a con-
tributing factor in this regard. This indeed
calls for a sea change in the perception
toward pharmacoeconomic studies and
their legitimacy in Nepal. That there is
not a single regional chapter, affiliated
with ISPOR, in Nepal underscores the state
of pharmacoeconomic studies in Nepal.
It is high time health experts and policy
makers in the country had a proper look
at pharmacoeconomics and its inherent
benefits.
Unlike other countries, pharmacoeco-
nomic studies in Nepal have not been
a dear of academia and industrial sec-
tor. Although academic institutions deal-
ing with pharmacy education are on the
rise in the country, they have still not been
inclined toward pharmacoeconomic stud-
ies. The chief reason for this is lack of fund-
ing for such studies, which should come
from the pharmaceutical industries or
public sector. In a scenario where pharma-
ceutical industries of Nepal are competing
with foreign industries for merely mak-
ing an impact in Nepalese pharmaceutical
market, delving into pharmacoeconomic
studies, and providing funding for these
studies remain an uncharted territory for
them. The research and development divi-
sion of pharma industries in Nepal is in its
incipient stage, so newer drug molecules
or newer combinations being discovered
in Nepal is not a recurring headline in
media. In fact, clinical trials in Nepal are
few and far between, with serious issues
withmethodology, ethics and the rationale
behind them (Sathian, 2011). In such a
situation, piggy-back pharmacoeconomic
evaluations, the type that is carried out
alongside clinical trials (O’Sullivan et al.,
2005), are out of equation, for standard-
ization of clinical trials is needed first in
present context of Nepal. In the same vein,
enough justice cannot be done at present
to naturalistic or effective pharmacoeco-
nomic trials, where data are collected in a
real-world situation and which is a good
substitute for the one done together with
clinical trials (Revicki and Frank, 1999;
Garrison et al., 2007). Research and devel-
opment of new pharmaceutical products is
still in its early days in Nepal; as a result,
the pharmacoeconomic studies pertaining
to new products are not what the country
is seeking for at the moment.
Pharmacoeconomic studies of the
existing medicines are more pertinent in
present context of Nepal. Pharmaceutical
market of Nepal is rife with me-too prod-
ucts (Budhathoki, 2012), which provide
minimal extra benefit than the respective
prototype product. Most of these prod-
ucts need to be sieved off so that the
budget and labor can be directed toward
such products that carry an added bene-
fit compared to its competing products.
Pharmacoeconomic evaluation of these
products can be exploited to ward off
such products. Although the price of these
products are less than the imported ones,
this lower price emanates from market
competition without any role of value
of these products. Value-based pricing,
however, is unlikely in the near future in
Nepal, so the primary concern has to be
ensuring cost-effectiveness. Observational
studies (Dreyer et al., 2010) and economic
modeling (Soto, 2002) are few such tech-
niques that can be exploited at present
for this very purpose. Observational stud-
ies may be prospective or retrospective
in nature, both of which can be car-
ried out in Nepal with few limitations.
Health database available at hospitals and
health centers can be utilized, which when
combined with cost-of-illness and epi-
demiological data make for a full-fledged
pharmacoeconomic evaluation. One such
study—the prospective one—has already
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been performed for effectiveness analysis
of pharmaceutical intervention in diabetes
mellitus at a tertiary care center in eastern
Nepal (Das et al., 2011). However, such
studies are very few in number, and they
have been conducted solely with academic
interest and not with an eye to inform the
health care decision making.
This brings us to the lack of phar-
macoeconomic studies influencing pol-
icy level decision making and lack of
funding for them in Nepal. That phar-
maceutical industries of Nepal are cur-
rently not in a position to fund such
studies further complicate the situation.
Nevertheless, these studies are of urgent
need in the country, and the initiatives
need to be taken. This has to come from
the public sector, which carries out differ-
ent health programs in the country. Health
sector of Nepal is assisted by fundings
from different International Organizations
for smooth running of most of its pro-
grams (Ministry of Health and Population,
2010). Moreover, the country has adopted
a sector-wide approach in health sector,
where funds are collected and directed
toward health programs under the lead-
ership of the Government. The public
sector has to take charge in pharmacoeco-
nomic studies as well, primarily by pro-
viding funding for these studies. It may
not be feasible to fund large number of
such studies; therefore, considerations also
need to be given toward establishing a
regional chapter in the country and adopt-
ing findings, with adjustments, of studies
conducted in other countries, wherever
possible.
Economic evaluation of pharmaceuti-
cal products is a must in developing coun-
tries like Nepal. Disseminating the findings
of pharmacoeconomic studies and assim-
ilating them in decision-making process
can lead to manufacture of cost-effective
medicine and better health budget alloca-
tion in the country.
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